Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha (Q79805117)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804923%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

title

Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804923%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference

Richard T Silver

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804923%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

publication date

1 August 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804923%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804923%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

volume

107

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804923%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804923%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

page(s)

451-458

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804923%20AND%20SRC:MED&resulttype=core&format=json

Recombinant interferon-alpha for treatment of polycythaemia vera

26 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22026

7 January 2021

Interferon-alpha 2b: a new treatment for polycythemia vera

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22026

7 January 2021

Interferon alpha in the treatment of polycythemia vera

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22026

7 January 2021

A prospective comparison between treatment with phlebotomy alone and with interferon-alpha in patients with polycythemia vera

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22026

7 January 2021

Efficacy of recombinant interferon-alpha (rIFN-alpha) in polycythaemia vera: a study of 17 patients and an analysis of published data

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22026

7 January 2021

Possible selective effects of interferon alpha-2b on a malignant clone in a case of polycythemia vera

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22026

7 January 2021

Polycythemia vera treated with recombinant interferon-alpha 2a: evidence of a selective effect on the malignant clone

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22026

7 January 2021

Cytogenetic conversion in a case of polycythaemia vera treated with interferon-alpha

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22026

7 January 2021

Interferon-alpha-induced morphological changes of megakaryocytes: a histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22026

7 January 2021

Impaired conversion of exogenous arachidonic acid by platelets to thromboxane B2 and correction of that deficiency by interferon-alpha

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22026

7 January 2021

Involvement of the fibrogenic cytokines, TGF-beta and bFGF, in the pathogenesis of idiopathic myelofibrosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22026

7 January 2021

TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22026

7 January 2021

Interferon-gamma in vivo reverses the increased platelet levels of platelet-derived growth factor and transforming growth factor-beta in patients with myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22026

7 January 2021

Vascular and neoplastic risk in a large cohort of patients with polycythemia vera

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22026

7 January 2021

Efficacy and safety of low-dose aspirin in polycythemia vera

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22026

7 January 2021

Clinical trials in myeloproliferative disorders: looking forward

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22026

7 January 2021

Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22026

7 January 2021

Management of patients with polycythaemia vera: results of a survey among Swedish haematologists

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22026

7 January 2021

The very-long-term course of polycythaemia: a complement to the previously published data of the Polycythaemia Vera Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22026

7 January 2021

Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22026

7 January 2021

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22026

7 January 2021

Identifiers

DOI

10.1002/CNCR.22026

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804923%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference